A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received June 14, 2019
- Accepted in final form September 6, 2019
- First Published November 8, 2019.
Author Disclosures
- Leoni Rolfes, MD*,
- Steffen Pfeuffer, MD,
- Tobias Ruck, MD,
- Susanne Windhagen, MD,
- Ilske Oschlies, MD,
- Hermann-Joseph Pavenstädt, MD,
- Linus Angenendt, MD,
- Heinz Wiendl, MD,
- Julia Krämer, MD* and
- Sven G. Meuth, MD, PhD*
- Leoni Rolfes, MD*,
NONE
NONE
(1) Merck Serono, travel reimbursements (2) Sanofi Genzyme, travel reimbursements
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steffen Pfeuffer, MD,
NONE
NONE
Commercial entity: Travel grants by Sanofi Genzyme, Merck, Biogen, Mylan
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity: Research support from DIAMED ans Merck Serono
NONE
NONE
Society: Research support from the German Multiple Sclerosis Society (DMSG)
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Ruck, MD,
TR served on a scientific advisory board for Genzyme, Merck and Novartis.
NONE
TR has received travel expenses from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen and Teva.
Guest associate editor for Frontiers in Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
TR has received financial research support from Genzyme and Novartis.
NONE
NONE
Supported by the German Ministry of Education, Science, Research and Technology (01GI1603D, to T.R. and S.G.M.; FKZ01FI1603A to HW, LK, and CCG)
NONE
NONE
NONE
NONE
NONE
NONE
- Susanne Windhagen, MD,
NONE
NONE
Honoraria for speaking engagements from Bayer Vital, Biogen, Merck-Serono, Novartis Pharma and TEVA-Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ilske Oschlies, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hermann-Joseph Pavenstädt, MD,
- Linus Angenendt, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Biogen (2) Evgen (3) Genzyme (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Aventis
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Actelion (3) Biogen (4) IGES (5) Johnson & Johnson (6) Novartis (7) Roche (8) Sanofi-Aventis (9) Swiss Multiple Sclerosis Society
NONE
NONE
NONE
(1) Biogen (2) GlaxoSmithKline GmbH (3) Roche Pharma AG (4) Sanofi-Genzyme.
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Julia Krämer, MD* and
- Sven G. Meuth, MD, PhD*
(1) German association for Multiple Sclerosis (2) German Society for Neurology (DGN)(3) Neurology Trust (4) Center for Clinical Studies (ZKS) (5) Max Planck Society
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
(1) PLoS One (editor) (2) DGNeurologie, founding member editorial board
(1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4  1402) (3)"NR2B selective NMDA-receptor Antagonists for Treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975)
NONE
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
NONE
NONE
NONE
Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
Research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
NONE
Research is funded by Else Kröner Fresenius Foundation, Hertie Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Clinic of Neurology with Institute of Translational Neurology (L.R., S.P., T.R., H.W., J.K., S.G.M.), University Hospital Münster; Department of Neurology and Neurological Rehabilitation (S.W.), Hospital Osnabrück, Am Finkenhügel 1; Department of Pathology (I.O.), Hematopathology Section and Lymph Node Registry, University-Hospital Schleswig-Holstein, Campus Kiel; Department of General Internal Medicine (H.-J.P.), Nephrology, Hypertensiology, and Rheumatology, University Hospital Münster; and Department of Hematology (L.A.), Hemostaseology, Oncology, and Pneumology, University Hospital Münster, Germany.
- Correspondence
Dr. Rolfes leoni.rolfes{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Mitigating alemtuzumab-associated autoimmunity in MSA “whack-a-mole” B-cell depletion strategyEthan Meltzer, Sarah Campbell, Benjamin Ehrenfeld et al.Neurology: Neuroimmunology & Neuroinflammation, August 07, 2020 -
Clinical/Scientific Notes
Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumabMika Saarela, Keerthi Senthil, Joanne Jones et al.Neurology, March 30, 2018 -
Article
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSFNora Möhn, Steffen Pfeuffer, Tobias Ruck et al.Neurology: Neuroimmunology & Neuroinflammation, December 11, 2019 -
Articles
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical TrialA.J. Coles, E. Fox, A. Vladic et al.Neurology, March 21, 2012